News

News Subscription

Jun 09. 2016
Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at ASCO meeting
Read more
Download
Apr 22. 2016
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
Read more
Download
Apr 21. 2016
Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting
Read more
Download
Apr 20. 2016
Basilea awarded contract by BARDA of up to USD 100 million funding for ceftobiprole phase 3 program
Read more
Download
Apr 15. 2016
Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Read more
Download
Mar 15. 2016
Basilea issues agenda for Annual General Meeting of Shareholders
Read more
Download
Mar 09. 2016
Basilea announces that The Lancet Infectious Diseases published results from the CRESEMBA® (isavuconazole) open-label study for the treatment of mucormycosis
Read more
Download
Mar 04. 2016
Basilea launching antifungal CRESEMBA® (isavuconazole) in Germany
Read more
Download
Mar 03. 2016
Basilea launching antifungal CRESEMBA® (isavuconazole) in the United Kingdom
Read more
Download
Feb 29. 2016
Basilea reports solid 2015 full-year results and is launching CRESEMBA®, its second hospital anti-infective, in Europe
Read more
Download